Amyris, Inc. (NASDAQ:AMRS) Files An 8-K Results of Operations and Financial Condition

0

Amyris, Inc. (NASDAQ:AMRS) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.


AMYRIS, INC. Exhibit
EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFilingEXHIBIT 99.1Amyris Reports Another Strong Quarter of Product Sales Growth and Expects Strong Finish for 2017 Q3 2017 GAAP revenues of $24.2 million (excludes $8.3 million for an upfront license agreement with Royal DSM executed in Q3 and fully paid early in Q4 2017) and Non-GAAP Q3 revenues of $32.5 million (includes upfront license agreement with Royal DSM),…
To view the full exhibit click here

About Amyris, Inc. (NASDAQ:AMRS)

Amyris, Inc. is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels. The Company focuses on a renewable hydrocarbon molecule called farnesene (Biofene). The Company is expanding its range of products across various categories divided into consumer and industrial applications. For consumer applications, the Company is developing and selling personal care products (which include ingredients for cosmetics and F&F), healthcare products and formulated end user products, such as Biossance brand skincare products and Muck Daddy brand hand cleaner product.

An ad to help with our costs